Abstract:Background: Lung cancer is the most prevalent type of cancer and the leading cause of cancer-related death. Chemotherapic resistance is one of the most prominent obstacles to treating lung cancer patients. Skp2 is upregulated, accompanied by the downregulation of MLKL and contributes to cisplatin resistance in NSCLC. We investigated the mechanism underlying the aberrant Skp2 linked to cisplatin resistance in NSCLC. Methods: We confirmed Skp2 and MLKL interaction by co-immunoprecipitation assays. We analyzed the biologic consequences of knockdown or overexpression of Skp2 using immunoblotting, immunoprecipitation, and immunohistochemistry. We analyzed Skp2-regulated MLKL degradation by ubiquitination assays. We tested the functions of Skp2, Skp2-ubiquitinated MLKL degradation and NSCLC chemoresistance by measuring cell viability, anchorage-independent cell growth, and mouse xenograft tumorigenesis. Results: Skp2 is overexpressed, accompanied by the downregulation of MLKL in human NSCLC tissues and cell lines. Knockdown of Skp2 inhibited cell viability, colony formation, and xenograft tumor growth. We demonstrated that Skp2 interacted with MLKL and promoted the ubiquitination and degradation of MLKL in NSCLC cell lines. Notably, Skp2 was highly expressed in cisplatin-resistant NSCLC cells and negatively correlated with MLKL. Furthermore, the silence of Skp2 partially restored MLKL and sensitized NSCLC cells to cisplatin. Interpretation: Our results suggest that the inhibition of Skp2-regulated MLKL ubiquitination may overcome NSCLC chemoresistance.Funding: This work was supported by the National Natural Science Foundation of China (No. 82073260, 81972837, 82003203, 81572280, 81401548) and the Natural Science Foundation of Hunan Province (No. 2021JJ31011, 2021JJ41058).Declaration of Interest: The authors have declared no conflicts of interest.Ethical Approval: This study was approved by the Ethics Committee of the Second Xiangya Hospital or the Ethics Committee of Xiangya Hospital, Central South University, China. All the patients provided their written informed consent. The animal experiments were approved by the Medical Research Animal Ethics Committee, Central South University, China.

Skp2-Ubiquitinated MLKL Degradation Confers Cisplatin-Resistant in NSCLC Cells